BPMC(Delisted)
Blueprint MedicinesยทNASDAQ
--
--(--)
BPMC fundamentals
Blueprint Medicines (BPMC) expects to report earnings on Aug 7, 2025, with estimated revenue of 171.34M (YoY +23.98%), and EPS at -0.53 (YoY +33.75%).
Revenue estimate / YoY
171.34M
+23.98%
EPS estimate / YoY
-0.53
+33.75%
Report date
Aug 7, 2025
EPS
Revenue
Revenue & Expenses
BPMC has released its 2025 Q1 earnings report, with revenue of 149.41M, reflecting a YoY change of 55.45%, and net profit of 496.00K, showing a YoY change of -99.44%. The Sankey diagram below clearly presents BPMC's revenue sources and cost distribution.
Key Indicators
Blueprint Medicines (BPMC) key financial stats and ratios, covering profitability, financial health, and leverage.
Blueprint Medicines (BPMC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Blueprint Medicines (BPMC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Blueprint Medicines (BPMC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Blueprint Medicines (BPMC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Blueprint Medicines (BPMC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
